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Introduction: It is not determined whether the continuous use of 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKI) is reasonable for patients with activating EGFR mutations, 
who have progressed with the drug.
Methods: We retrospectively analyzed the data from 2002 to 2010 
of consecutive patients who had advanced non–small-cell lung can-
cer (NSCLC) harboring activating EGFR mutations and showed 
radiological disease progression after EGFR-TKI treatment as the 
first-line or second-line setting. We classified them into two groups: 
continuous EGFR-TKI and switching to chemotherapy, and com-
pared the clinical outcomes. Multivariate analysis for survival was 
performed including age, sex, Eastern Cooperative Oncology Group 
performance status (0–1/ 2–4), brain metastasis, EGFR mutations 
(deletions in exon 19 versus L858R), continuous EGFR-TKI (yes/
no), and initiation of EGFR-TKI (first versus second).
Results: A total of 551 NSCLC patients were screened for EGFR 
mutations in the period, and 186 patients had activating EGFR muta-
tions. To explore the potential use of EGFR-TKI beyond progres-
sive disease (PD), 64 patients were selected and analyzed. There 
were 13 men and 51 women, and median age was 65.5 years (range, 
42–86). Among them, 31 patients had deletions in exon 19, and 33 
had point mutation of L858R in exon 21. Thirty-nine patients were 
continuing EGFR-TKI beyond PD; 25 patients were switched to 
cytotoxic chemotherapy alone. The median overall survival was 32.2 
months in the patients continuing EGFR-TKI, and 23.0 months in 
the patients switching to chemotherapy, presenting a significant dif-
ference between the two groups (p = 0.005). Cox analysis showed 
that continuous EGFR-TKI after PD (hazards ratio 0.42, 95% confi-
dence interval: 0.21–0.83, p = 0.013) was associated with improved 
survival.
Conclusion: Continuous use of EGFR-TKI beyond PD may prolong 
overall survival compared with switching to cytotoxic chemotherapy 
in patients with activating EGFR mutations. A prospective study will 
be needed to confirm our results.
Key Words: Advanced non–small-cell lung cancer, Epidermal growth 
factor receptor mutation, Epidermal growth factor receptor tyrosine 
kinase inhibitor.
(J Thorac Oncol. 2012;7: 1722–1727)
Lung cancer represents the leading cause of death from cancer in Japan as well as in the European Union and 
the United States, and non–small-cell lung cancer (NSCLC) 
accounts for approximately 85% of lung cancers.1–3 Many 
patients with NSCLC have advanced disease at diagnosis 
and a poor prognosis with median survival time of 8 to 
10 months. However, the clinical course and survival have 
changed dramatically after epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKI) were introduced to 
a subgroup of patients.4,5 Somatic mutations in the EGFR 
have been demonstrated as the most important biomarker 
in predicting the clinical outcome treated with EGFR-
TKI. The activating EGFR mutations including deletions 
in exon 19 and L858R in exon 21 encompass most of the 
tyrosine kinase-binding domain of EGFR.6 A couple of 
phase III studies showed that gefitinb or erlotinib provided a 
significant clinical benefit in NSCLC patients with activating 
EGFR mutations, with a response of more than 70% in 
NSCLC patients harboring activating EGFR mutations, with 
progression-free survival (PFS) ranging from 9.2 to 13.1 
months and median overall survival (OS) from 21.0 to 30.9 
months.5,7–11
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However, NSCLC develops resistance to EGFR-TKI, 
with the eventual appearance of progressive disease (PD).12,13 
Although guidelines recommend that EGFR-TKI should be 
changed to cytotoxic chemotherapy including platinum dou-
blet after failure,14,15 the result of this treatment strategy after 
acquiring resistance to EGFR-TKI is not clear in a practi-
cal setting. Rapid tumor increase after stopping EGFR-TKI 
after PD has been reported, and there are some suggestions 
that continuing EGFR-TKI after PD is a reasonable option for 
patients with activating EGFR mutation.16,17 To date there are 
no studies examining the efficacy of continuing EGFR-TKI 
treatment after PD in patients with activating EGFR mutation, 
and we explored the potential of allowing the continuation of 
EGFR-TKI after the failure of EGFR-TKI.
PATIENTS AND METHODS
Patients
Clinical information was retrospectively obtained from 
the NSCLC patients treated from June 2002 to February 2010 
through a database from the National Hospital Organization 
Kinki-chuo Chest Medical Center, Japan, and the data was 
updated in December 2011. We examined patients with 
advanced NSCLC harboring activating EGFR mutations (dele-
tions in exon 19 or L858R), who were treated with EGFR-TKI 
in first- or second-line setting, and showed radiological progres-
sion after treatment with EGFR-TKI. We confirmed PD using 
the Response Evaluation Criteria in Solid Tumors 1.0. One 
radiologist (OT) reviewed all the patients and determined all 
the responses to EGFR-TKI independently. We then classified 
the patients into two groups based on the following treatment: 
continuous EGFR-TKI and switching to chemotherapy. We 
defined beyond PD as continuing EGFR-TKI after confirming 
PD. The patients who were readministrated EGFR-TKI after the 
cytotoxic chemotherapy were excluded in this study. A genetic 
analysis had been performed to detect EGFR mutations from 
exons 18 to 21. The nucleotide sequence of the kinase domain 
of the EGFR gene had been determined using polymerase chain 
reaction INVADER assay of the individual exons.
Statistical Analysis
Associations among clinical characteristics were ana-
lyzed by Fisher’s exact test or Mann–Whitney U test. OS was 
defined as a period from the start of first-line treatment of che-
motherapy or EGFR-TKI to the date of death by any cause, or 
the date when the patient was last known to be alive. This was 
analyzed by the Kaplan–Meier method. The differences between 
the two groups were tested using the log-rank test. Multivariate 
analysis for survival was performed with Cox regression model 
using the following covariates: age, sex, Eastern Cooperative 
Oncology Group performance status (PS), histology, stage, 
brain metastasis, EGFR mutations (deletions in exon 19 versus 
L858R), continuous EGFR-TKI, and initiation of using EGFR-
TKI (first versus second). Statistical analysis was performed 
using SAS 9.1.3 (SAS Institute Inc., Cary, NC). This study was 
approved by the Institutional Review Boards of the National 
Hospital Organization Kinki-Chuo Chest Medical Center.
RESULTS
Patient Characteristics
EGFR mutations were screened in 551 patients 
(Fig. 1). Activating EGFR mutations were detected in 186 of 
551 patients (33.8%). One hundred and thirty-five patients 
with activating EGFR mutations were treated with EGFR-TKI. 
Of the 135 patients who received EGFR-TKI, 112 patients 
received EGFR-TKI as first line or second line; 23 patients 
received EGFR-TKI at first time after second line. Among the 
FIGURE 1. Flowchart of patient 
selection. EGFR-TKI, epidermal 
growth factor receptor tyrosine 
kinase inhibitors; PD, progressive 
disease.
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112 patients who received EGFR-TKI in first line or second line, 
89 were recognized as having PD during EGFR-TKI treatment, 
whereas 23 were not recognized as PD. Among 89 patients, 
64 patients were selected for analysis and 25 patients were 
excluded for a variety of reasons; 15 patients received cytotoxic 
chemotherapy followed by readministration of EGFR-TKI, 
four patients received cytotoxic chemotherapy combined with 
EGFR-TKI, and six patients received just best supportive care 
after the failure. Demographics of the 64 patients are listed in 
Table 1. No differences were observed between the two groups, 
except that the patients in the continuous group were signifi-
cantly older than those in the group switching to chemotherapy 
(p = 0.008). Median duration of follow-up period for survival 
was 25.7 months (range, 5.7–75.1). There were 13 men and 51 
women with activating EGFR mutations, and median age was 
65.5 years (range, 42–86). A total of 31 patients had deletions 
in exon 19, and 33 had a point mutation resulting in L858R, and 
none of them had double mutations. Thirty-nine patients were 
continuing EGFR-TKI after PD. Twenty-five patients switched 
EGFR-TKI to cytotoxic chemotherapy regimens: carboplatin/
paclitaxel (2 patients), carboplatin/gemcitabine (2 patients), 
docetaxel (6 patients), pemetrexed (9 patients), and S-1 (6 
patients) The objective response (complete response + par-
tial response) to initial EGFR-TKI was seen in the 22 patients 
(65%) in the continuous group among the 34 patients evalu-
able for the response, and in 14 patients (64%) in the switching 
group among 22 patients. There was no significant difference 
between the two groups (p = 0.935). As for the relapse site after 
EGFR-TKI treatment, 29 patients (74.3%) were confirmed 
at primary region, six (15.4%) at brain site, three (7.7%) at 
bone site, and one (2.6%) at liver in the continuous group; 21 
patients (84.0%) were confirmed as PD at primary region, three 
(12.0%) at brain site, and one (4.0%) at liver, in the switch-
ing group. There was also no significant difference between 
the two groups (p = 0.360). Grade 3 or 4 hematologic toxic-
ity after PD was observed in one patient (2.9%) continuing 
in the EGFR-TKI group, whereas nine patients (36.0%) were 
observed in the switching to chemotherapy group. No elevated 
serum value of progastrin-releasing peptide, a selective tumor 
marker for small-cell lung cancer (SCLC), was observed at the 
time of PD, suggesting that they had no conversion to SCLC.
Survival Analysis for Continuous EGFR-TKI  
Versus Switching to Chemotherapy
Univariate analysis showed that the median OS was 
32.2 months in the patients continuing EGFR-TKI, and 23.0 
months in those switching to cytotoxic chemotherapy. As 
shown in the survival curves in Figure 2, there was a signifi-
cant difference between the two groups (p = 0.005).
In the patients receiving first-line EGFR-TKI treatment, 
PFS was 14.4 months in the continuous group (n = 18) and 
12.4 months in the switching group (n = 9). Although the 
continuous group had longer PFS numerically, there was no 
significant difference (p = 0.176). Multivariate analysis in a 
Cox model showed that better PS (hazards ratio [HR] 3.16, 
95% confidence interval [CI]: 1.50–6.68, p = 0.026) and con-
tinuous EGFR-TKI treatment after PD (HR 0.42, 95%CI: 










(n = 25) P
Age (yrs)
 Median (range) 65.5(42–86) 69(45–86) 58(42–82) 0.008
Sex
 Male/Female 13/51 6/33 7/18 0.221
Smoking history
 Current smoker/former smoker/never smoker 8/9/47 4/6/29 4/3/18 0.838
ECOG performance status
 0–1/2–4 52/12 32/7 20/5 0.838
Tumor type
 Adenocarcinoma/ non–small-cell carcinoma 60/4 37/2 23/2 0.640
Tumor stage
 IIIA/ IIIB/ IV/postoperative recurrence 2/11/34/17 1/5/22/11 1/6/12/6 0.654
Brain metastasis
 No/yes 48/16 29/10 19/6 0.882
Site of progressive disease
 Primary region /brain/bone/abdomen 50/9/3/2 29/6/3/1 21/3/0/1 0.538
EGFR mutation
 Deletions in exon 19/L858R 31/33 19/20 12/13 0.955
Initiation of EGFR-TKI
 1st line/2nd line 27/37 18/21 9/16 0.422
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors; ECOG, Eastern Cooperative Oncology Group.
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(Table 2). Continuous treatment of EGFR-TKI was a signifi-
cant and independent prognostic factor in patients with acti-
vating EGFR mutations. Any other variables such as age, sex, 
brain metastasis, type of EGFR mutations, and initiation of 
EGFR-TKI were not associated with OS.
DISCUSSION
In this retrospective study, we have shown that NSCLC 
patients with EGFR mutations, who continued EGFR-TKI 
treatment after PD had significantly longer survival compared 
with those who switched to cytotoxic chemotherapy. This 
study suggests that continuing EGFR-TKI treatment after dis-
ease progression might be a reasonable option for improving 
patient survival.
There are a few other studies investigating the treat-
ment of EGFR-TKI after PD, but we believe this is the first 
report suggesting a survival benefit of continuing EGFR-TKI 
treatment for patients with EGFR mutations beyond disease 
progression.
In previous studies, Maruyama et al.18 retrospectively 
analyzed 60 patients who had treatment failure after achiev-
ing disease control with gefitinib. These patients were treated 
with or without continuing gefitinib. Continuing the drug was 
associated with a better survival based on multivariate anal-
yses (HR 0.51, 95%CI: 0.26–0.98, p = 0.042).18 Faehling et 
al.19 also reported retrospectively that NSCLC patients treated 
with erlotinib, whose disease progressed after long-term erlo-
tinib, responded and showed treatment with TKI after disease 
FIGURE 2. Overall survival curves 
on the basis of the time from the 
initiation of first-line chemotherapy. 
Kaplan–Meier estimates of con-
tinuous EGFR-TKI and switching to 
chemotherapy. EGFR-TKI, epidermal 
growth factor receptor tyrosine 
kinase inhibitors.









ECOG performance status 1.50–6.68 0.026
 0–1 1.00
 2–4 3.16
Brain metastasis 0.44–1.99 0.849
 Yes 1.00
 No 0.93
EGFR mutation 0.62–2.39 0.562
 Deletions in exon 19 1.00
 L858R 1.22
Continuous EGFR-TKI 




Initiation of EGFR-TKI 0.33–1.37 0.272
 1st line 1.00
 2nd line 0.67
HR, hazards ratio; CI, confidence interval; EGFR, epidermal growth factor   
receptor; TKI, tyrosine kinase inhibitors; ECOG, Eastern Cooperative Oncology  
Group.
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progression, leading to prolonged OS. However, both the stud-
ies did not analyze patients based on EGFR mutation status.
The concept of beyond PD has been established and 
accepted in the treatment of several malignant tumors. 
Bevacizumab beyond initial PD could play an important role 
in improving the OS in patients with metastatic colorectal can-
cer.20 Also, trastuzumab beyond PD offers a survival benefit 
to breast cancer with human EGFR type 2.21 In addition, con-
tinuing imatinib over disease progression is considered to be 
an option for relapsed or progressed advanced gastrointestinal 
stromal tumor patients.22 These studies indicate that continuing 
the treatment that blocks the cascade of oncogenes may still 
have a clinical benefit when tumor depends on only one onco-
gene. On the basis of these results and our data, the concept can 
be applied to advanced NSCLC. Gregory et al.16 reported that 
stopping EGFR-TKI use results in symptomatic progression, 
and an increase in standardized uptake value of positron emis-
sion tomography and an increase in tumor size in patients with 
NSCLC who develop acquired resistance. Our study enhanced 
this observation and could show an extension of the OS.
It seems that the patients with activating EGFR 
mutations are able to maintain quality of life (QOL) by 
continuing EGFR-TKI. Inoue et al.23 reported the efficacy and 
feasibility of gefitinib for patients with poor PS and NSCLC 
harboring EGFR mutations. PS improvement was observed 
in 79% (p < 0.00005) and these patients maintained a good 
QOL.23 In the present study, severe hematologic toxicity 
was more observed in the group switching to chemotherapy. 
Four patients who changed to cytotoxic chemotherapy died 
within a few months after EGFR-TKI was stopped and 
experienced rapid tumor growth and toxicities because of the 
chemotherapy. EGFR-TKI can be beneficial in reducing risks 
associated with side effects caused by cytotoxic chemotherapy. 
In NSCLC treatment, consideration for maintaining QOL and 
the avoidance of adverse events is considered to be of vital 
importance, and therefore this therapy may be reasonable after 
the failure of EGFR-TKI treatment, particularly to the patients 
showing poor PS.
The strategy regarding how to treat NSCLC after acquir-
ing resistance to EGFR-TKI has been discussed, but there is 
still a challenge to overcome resistance and no practical and 
clinical method has been established to date. We suggest con-
tinuation of EGFR-TKI is reasonable for the suppression of 
EGFR-TKI sensitive clones, and adding drugs on EGFR-TKI 
can be a promising option to treat the patients. The treatment 
of cytotoxic chemotherapy has been reported in combina-
tion with EGFR-TKI as well as antibody against c-MET and 
EGFR.24,25 Jänne and colleagues26 reported the efficacy of 
combination therapy with erlotinib and carboplatin/paclitaxel 
compared with erlotinib alone. OS in the mutation-positive 
patients was 38.1 months in the combination group whereas 
it was 31.3 months in the erlotinib-alone group.26 Our group 
has also conducted a prospective phase II study to evaluate the 
efficacy and toxicity of adding pemetrexed to EGFR-TKI after 
relapse in patients with active EGFR mutations. In the study, 
promising data have been obtained, and PFS was 6.2 months 
and disease control rate was 86.4% with mild toxicities.27
The mechanism to acquire resistance has been inten-
sively studied and recent reports showed that half the relapsed 
patients had a secondary mutation that substitutes methionine 
for threonine at amino acid 790 in EGFR, and approximately 
20% patients had MET amplification.12,13 In addition, a new 
phenomenon of transforming from NSCLC into SCLC was 
demonstrated.28 Although we did not conduct rebiopsy in our 
patients, there were no increasing progastrin-releasing pep-
tides and we could not find clear evidence to confirm the trans-
formation at least in tumor-marker levels specific for SCLC. 
Further molecular study of the resistant tumor taken from 
rebiopsy are needed.
There are some limitations in our study. The sample size 
is small, and the nature of progressive disease in the EGFR-
mutated patients treated with EGFR-TKI is varying. The 
physicians’ decision regarding continuation or switching to 
chemotherapy might vary as a result of retrospective analy-
sis. Although there was no significant difference between 
the two groups in response to initial EGFR-TKI and relapse 
site during or after the treatment, the continuous group had 
longer PFS numerically. The physicians’ decision might be 
influenced by the duration of EGFR-TKI use. However, the 
effectiveness of EGFR-TKI for the patients who received che-
motherapy after having long PFS might be underestimated 
in this study, because those who had re-challenge of EGFR-
TKI after cytotoxic chemotherapy were not counted (Fig. 1). 
However, the patients in the continuous EGFR-TKI group 
were older than the those in the group switching to chemo-
therapy. Older patients might tend to continue the EGFR-TKI 
treatment because of a concern with the toxicity of cytotoxic 
chemotherapy. We would need a prospective trial to exam-
ine the head-to-head comparison of continuing EGFR-TKI 
treatment versus switching to chemotherapy on disease pro-
gression. The median OS was 32.3 months in the continuous 
group and 23.0 months in the switching group. Previous stud-
ies showed that the median OS in EGFR-mutated patients was 
between 21.0 and 30.9 months.5,7–11
In this study, we defined a PD based on Response 
Evaluation Criteria in Solid Tumors, which is originally used 
for cytotoxic chemotherapy. It may be inappropriate to use 
these criteria to evaluate a PD after use of a molecular-target 
agent. Jackman et al.29 proposed a clinical definition of PD 
for EGFR-TKI, which was limited to the status within the 
last 30 days while on continuous treatment with EGFR-TKI 
after obtaining objective clinical benefit from the treatment. 
According to this definition, if tumors are not growing rap-
idly in 30 days, continuing EGFR-TKI treatment would be a 
reasonable option. How to evaluate a PD after EGFR-TKI use 
will be critical, and we need to verify whether this definition 
is useful in clinical practice.
In conclusion, continuation of EGFR-TKI beyond PD is 
one of the choices after the failure of EGFR-TKI treatment in 
patients with activating EGFR mutations. Further evaluation 
of the treatment after the failure of EGFR-TKI will be needed 
in a prospective study in the future.
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